🚀 VC round data is live in beta, check it out!
Medartis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Medartis and similar public comparables like Shinva, Sinocare, Kuros Biosciences, Staar Surgical and more.
Medartis Overview
About Medartis
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from EMEA and also has a presence in APAC, LATAM, and USA.
Founded
1997
HQ
Employees
949
Website
Financials (LTM)
EV
$1B
Medartis Financials
Medartis reported last 12-month revenue of $365M and EBITDA of $61M.
In the same LTM period, Medartis generated $61M in EBITDA and $14M in net income.
Revenue (LTM)
Medartis P&L
In the most recent fiscal year, Medartis reported revenue of $345M and EBITDA of $59M.
Medartis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $365M | XXX | $345M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $262M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $61M | XXX | $59M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $14M | XXX | $11M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | — | — | $124M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Medartis Stock Performance
Medartis has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Medartis' stock price is $103.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.2% | XXX | XXX | XXX | $0.86 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMedartis Valuation Multiples
Medartis trades at 3.9x EV/Revenue multiple, and 23.7x EV/EBITDA.
EV / Revenue (LTM)
Medartis Financial Valuation Multiples
As of April 20, 2026, Medartis has market cap of $1B and EV of $1B.
Equity research analysts estimate Medartis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medartis has a P/E ratio of 94.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | 23.7x | XXX | 24.6x | XXX | XXX | XXX |
| EV/EBIT | 51.9x | XXX | 64.6x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.5x | XXX | XXX | XXX |
| P/E | 94.5x | XXX | 119.9x | XXX | XXX | XXX |
| EV/FCF | 285.7x | XXX | 120.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Medartis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Medartis Margins & Growth Rates
Medartis' revenue in the last 12 month grew by 21%.
Medartis' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Medartis' rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medartis' rule of X is 72% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Medartis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 34% | XXX | 29% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 72% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 47% | XXX | 48% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 16% | XXX | 17% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | 67% | XXX | 75% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Medartis Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Medartis | XXX | XXX | XXX | XXX | XXX | XXX |
| Shinva | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocare | XXX | XXX | XXX | XXX | XXX | XXX |
| Kuros Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Staar Surgical | XXX | XXX | XXX | XXX | XXX | XXX |
| El.En. Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medartis M&A Activity
Medartis acquired XXX companies to date.
Last acquisition by Medartis was on XXXXXXXX, XXXXX. Medartis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Medartis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMedartis Investment Activity
Medartis invested in XXX companies to date.
Medartis made its latest investment on XXXXXXXX, XXXXX. Medartis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Medartis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Medartis
| When was Medartis founded? | Medartis was founded in 1997. |
| Where is Medartis headquartered? | Medartis is headquartered in Switzerland. |
| How many employees does Medartis have? | As of today, Medartis has over 949 employees. |
| Is Medartis publicly listed? | Yes, Medartis is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Medartis? | Medartis trades under MED ticker. |
| When did Medartis go public? | Medartis went public in 2018. |
| Who are competitors of Medartis? | Medartis main competitors are Shinva, Sinocare, Kuros Biosciences, Staar Surgical. |
| What is the current market cap of Medartis? | Medartis' current market cap is $1B. |
| What is the current revenue of Medartis? | Medartis' last 12 months revenue is $365M. |
| What is the current revenue growth of Medartis? | Medartis revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Medartis? | Current revenue multiple of Medartis is 3.9x. |
| Is Medartis profitable? | Yes, Medartis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medartis? | Medartis' last 12 months EBITDA is $61M. |
| What is Medartis' EBITDA margin? | Medartis' last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Medartis? | Current EBITDA multiple of Medartis is 23.7x. |
| What is the current FCF of Medartis? | Medartis' last 12 months FCF is $5M. |
| What is Medartis' FCF margin? | Medartis' last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Medartis? | Current FCF multiple of Medartis is 285.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.